All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How might itacitinib prophylaxis impact haplo-HSCT outcomes in the future?
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Ramzi Abboud, Washington University School of Medicine, St. Louis, US. We asked, how might itacitinib prophylaxis impact haploidentical hematopoietic stem cell transplantation (haplo-HSCT) outcomes in the future?
How might itacitinib prophylaxis impact haplo-HSCT outcomes in the future?
In this video, Abboud discusses the role of JAK inhibitors (including itacitinib and ruxolitinib) in the haplo-HSCT setting. He also discusses a pilot study, which him and his team conducted at Washington University School of Medicine, investigating itacitinib in the haplo-HSCT setting (NCT03755414).
More about...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox